Pfizer Inc. PFE
28.67
0.26
0.92%
as of 25 Sep
- Market cap
- $161.7B
- P/E
- 37.7×
Follow PFE
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Pfizer Inc. (PFE) Net income
Pfizer Inc.'s net income for fiscal 2025 was $7.8B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.4B. Over the past ten years it has ranged from $2.2B (fiscal 2023) to $31.4B (fiscal 2022); the current reading is higher than 36% of that period. Pfizer Inc. ranks 11th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $7.8B | (3.10%) |
| FY2024 | $8.1B | 273.59% |
| FY2023 | $2.2B | (93.13%) |
| FY2022 | $31.4B | 42.60% |
| FY2021 | $22.0B | 139.53% |
| FY2020 | $9.2B | (42.73%) |
| FY2019 | $16.1B | 43.51% |
| FY2018 | $11.2B | (47.61%) |
| FY2017 | $21.4B | 194.71% |
| FY2016 | $7.2B | 3.72% |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$238.0M | — |
| Mar 2026 | $2.7B | — |
| Dec 2025 | −$1.6B | — |
| Sep 2025 | $3.6B | 21.28% |
| 42 more quarters | Free account |
Against its own ten years
Low $2.2B
High $31.4B
Ten-year median
$9.2B
Current reading's percentile
36
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| AMGN Amgen Inc. compare | $8.7B |
| GSK GSK PLC Sponsored ADR compare | $6.9B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. | $4.4B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on PFE
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement